99.9% USP Bp Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone CAS NO.53179-13-8

Hebei yanxi chemical co. LTD.  has expanded a compositive entity from initially only as a small manufacturer. The company dedicated to the development, production and marketing of chemicals. 
After many years of efforts, we have established stable and friendly business relations with dozens of European and American pharmaceutical companies, multinational chemical companies and importers.At home and many production plants and research and development units have established long - term commission processing and production relations.We have a number of laboratories specializing in technology development and custom synthesis, as well as some production bases, mainly in hebei, sichuan, jiangsu and shandong.
Our company possesses the right of self-support import & export, a strong technical force and advanced processing equipments. The quality of the products has been strictly inspected and all kinds of index have reached or exceeded domestic and international standards.
Looking to the future, we will adhere to the spirit of “professional, innovative, integrity, development”, and adhere to the management philosophy of “customer-orientation and pursing development via integrity” and through which to provide customers with first-class products and service. We sincerely welcome friends both at home and abroad to visit our company and hope to achieve win-win cooperation with you!

99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone

Product Name: Pirfenidone
Synonyms: 5-Methyl-1-phenylpyridine-2(1H)-one;S-7701;5-methyl-1-phenyl-2-pyridone;5-methyl-1-phenyl-pyridin-2-one;5-methyl-1-phenylpyridin-2-one;Pirfenidone, >=99%;5-methyl-1-phenylpyridin-2(1H)-one;Pirfenidone(S-7701,AMR-69)
CAS: 53179-13-8
MF: C12H11NO
MW: 185.22
EINECS: 621-260-7
Appearance: white to pale yellow powder
Uses: Pirfenidone is a broad-spectrum antifibrotic drug that modulates diverse cytokine action involving TGF-β, TNF-α, epidermal growth factor, platelet-derived growth factor,vascular endothelial growth factor, insulin-like growth factor 1, fibroblast growth factor, and others.Pirfenidone has been effective in the prevention and regression of pulmonary fibrosis, peritoneal sclerosis, hepatic cirrhosis, uterine fibromyoma, and other scarring and fibrotic conditions. It doesn't cure the condition or reverse any existing scarring but it can effectively slow down the rate of lung function decline by about 50%. In the UK, Pirfenidone is currently only approved for treating IPF, and not for other forms of pulmonary fibrosis.

Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.